logo
Mote scientists, partners unveil arsenal of tools aimed at fighting red tide

Mote scientists, partners unveil arsenal of tools aimed at fighting red tide

Yahoo30-01-2025
SARASOTA, Fla. (WFLA) – Mote Marine Laboratory received millions of dollars from the state for a red tide mitigation initiative a few years back. Now, alongside their partners, scientists unveiled some of the tools they've developed to tackle the harmful algal blooms.
'The state of Florida is leading in the U.S. and indeed leading in the world in developing new technologies to fight, not only red tide but other harmful algal blooms in freshwater and marine ecosystems all around the United States and all around the world,' said Mote CEO Dr. Michael Crosby.
QVC US and HSN operations close campus in St. Petersburg
Scientists looked at more than 300 different approaches and narrowed it down to about two dozen. Three of those have already received state and federal approvals to be deployed.
'Our mantra is with all of these technologies.. none of them will do any greater harm to the environment than the red tide is already doing,' said Dr. Crosby.
Mote broke down three initiatives ready for deployment in a news release this week.
Principal Investigator: Dr. Dana WetzelCLEAR is a novel, naturally derived biocide developed by Mote's Environmental Laboratory for Forensics. Harnessing the properties of natural plant-based compounds, CLEAR targets K. brevis with no environmental impact. CLEAR's active ingredients are classified as Generally Recognized as Safe (GRAS) by the FDA, and studies show no measurable accumulation in the environment. The all-natural biocide degrades fully within half a day, ensuring its safety for marine ecosystems. Regulatory approvals from the EPA, FDACS, and DEP allow for rapid deployment of CLEAR in the event of a bloom.
Mote has developed multiple formulations of CLEAR to ensure versatility. Engineered particle treatments can be deployed on surface waters via vessel-mounted blowers, drones, or backpack sprayers. For underwater applications, remotely operated vehicles (ROVs) or autonomous underwater vehicles (AUVs) deliver the liquid form directly into blooms. This liquid application may also be deployed sub-surface with a specially equipped boat. CLEAR-embedded dissolvable beads provide sustained protection for 30-60 days, ideal for canals, marinas, and other vulnerable areas. This multi-faceted approach ensures targeted and effective mitigation.
Principal Investigator: Dr. Rich PierceXtreme is a natural, non-toxic water treatment product developed by Heartland Energy Group. Previously used for blue-green algae (a freshwater HAB), Xtreme has demonstrated significant effectiveness against K. brevis. Lab testing and mesocosm experiments at Mote confirmed Xtreme's ability to reduce red tide cells and brevetoxins while posing no harm to marine life, including commercially important clams. Xtreme offers a natural solution that could help control blooms. This product is deployed by a large handheld sprayer.
Principal Investigator: Dr. Rich PierceOZONIX® is a patented, chemical-free water treatment technology that combines several processes to eliminate K. brevis cells and their toxins. It uses hydrodynamic cavitation (a process that creates bubbles in the water to break apart harmful substances), ozone injection (adding ozone gas to the water, which helps break down toxins), ultrasonic acoustic cavitation (using sound waves to create bubbles that break down harmful materials), and electrochemical oxidation (a process where electricity helps remove contaminants). These techniques work by running large hoses into the water that are connected to a trailer outfitted with a complex water system. Together, these techniques effectively address the red tide algae and its toxins.
When and where to deploy these technologies will be up to state and federal leaders.
'This is huge for the state of Florida, it is huge for the United States, it is huge for the world to be able to fight these very toxic negative impacts to our environment, to our economy and to our quality of life,' said Dr. Crosby. 'We are working very patiently, but very deliberately through the permitting process for the other dozen and a half technologies. We need them all to be approved, but we do have to work through those processes. We are ready to deploy now. What we need to do is a scale this up so that we can have large-scale deployment of all of these technologies,' he continued.
Partners of Mote include Senior Global Product Manager, Heartland Energy Group, Prescott Clean Water, AquaTech Eco Consultants, Hull's Environmental Services, and A-C-T Environmental & Infrastructure.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ClostraBio, Inc. Obtains Self-Affirmed GRAS Status for Next-Gen Probiotic Ingredient CLB101™
ClostraBio, Inc. Obtains Self-Affirmed GRAS Status for Next-Gen Probiotic Ingredient CLB101™

Yahoo

time29-07-2025

  • Yahoo

ClostraBio, Inc. Obtains Self-Affirmed GRAS Status for Next-Gen Probiotic Ingredient CLB101™

CHICAGO, July 29, 2025--(BUSINESS WIRE)--ClostraBio, Inc., a biotech company pioneering microbiome-based solutions for gastrointestinal health, today announced that its unique, next-generation probiotic strain, Anaerostipes caccae CLB101™, has been granted self-affirmed GRAS (Generally Recognized as Safe) status by a panel of scientific experts. This milestone clears the path for CLB101™ to enter the U.S. market as the first and only commercially available strain of Anaerostipes caccae. A strict anaerobe isolated from a healthy human, CLB101™ has been identified as a strain critical to gut health through its direct production of butyrate in targeted areas of the lower intestine. Butyrate is widely known as a key molecule to support gut health, and its mechanisms of action include strengthening intestinal barrier integrity, providing immune support, and promoting a diverse microbiome. "Receiving GRAS status marks a critical milestone for ClostraBio and validates the safety of CLB101™ as we move towards commercial launch," said Ritu Shah, CEO of ClostraBio. "This recognition reinforces our commitment to advancing safe, science-driven solutions that can help support gut health for the many people who are struggling today." The GRAS designation follows rigorous review of safety data, including genomic characterization, multiple toxicology studies, and a demonstrated manufacturing process with stringent quality control. ClostraBio is preparing to launch CLB101™ as a probiotic supplement in Fall 2025, through both direct and partnered distribution channels, including a strategic collaboration with a leading healthcare practitioner-focused supplement brand. For more information on ClostraBio and CLB101™, please visit About ClostraBio: ClostraBio is leveraging a science driven, multi-pronged approach to address conditions of the lower gut, using novel biotechnology to harness natural pathways. The Company is developing a next-generation probiotic that produces butyrate in the lower gut to impact intestinal barrier function and promote gut health, as well as a novel polymeric prodrug platform designed to deliver small molecules to the lower gut. ClostraBio was spun out of the University of Chicago and is incubated at Portal Innovations. View source version on Contacts Media Contact:Nick Pennebaker, Sr. Director of Marketing and CommunicationsPortal InnovationsEmail: Company/Business Contact:Ritu Shah, CEOClostraBio, info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ClostraBio, Inc. Obtains Self-Affirmed GRAS Status for Next-Gen Probiotic Ingredient CLB101™
ClostraBio, Inc. Obtains Self-Affirmed GRAS Status for Next-Gen Probiotic Ingredient CLB101™

Business Wire

time29-07-2025

  • Business Wire

ClostraBio, Inc. Obtains Self-Affirmed GRAS Status for Next-Gen Probiotic Ingredient CLB101™

CHICAGO--(BUSINESS WIRE)--ClostraBio, Inc., a biotech company pioneering microbiome-based solutions for gastrointestinal health, today announced that its unique, next-generation probiotic strain, Anaerostipes caccae CLB101™, has been granted self-affirmed GRAS (Generally Recognized as Safe) status by a panel of scientific experts. This milestone clears the path for CLB101™ to enter the U.S. market as the first and only commercially available strain of Anaerostipes caccae. A strict anaerobe isolated from a healthy human, CLB101™ has been identified as a strain critical to gut health through its direct production of butyrate in targeted areas of the lower intestine. Butyrate is widely known as a key molecule to support gut health, and its mechanisms of action include strengthening intestinal barrier integrity, providing immune support, and promoting a diverse microbiome. 'Receiving GRAS status marks a critical milestone for ClostraBio and validates the safety of CLB101™ as we move towards commercial launch,' said Ritu Shah, CEO of ClostraBio. 'This recognition reinforces our commitment to advancing safe, science-driven solutions that can help support gut health for the many people who are struggling today.' The GRAS designation follows rigorous review of safety data, including genomic characterization, multiple toxicology studies, and a demonstrated manufacturing process with stringent quality control. ClostraBio is preparing to launch CLB101™ as a probiotic supplement in Fall 2025, through both direct and partnered distribution channels, including a strategic collaboration with a leading healthcare practitioner-focused supplement brand. For more information on ClostraBio and CLB101™, please visit About ClostraBio: ClostraBio is leveraging a science driven, multi-pronged approach to address conditions of the lower gut, using novel biotechnology to harness natural pathways. The Company is developing a next-generation probiotic that produces butyrate in the lower gut to impact intestinal barrier function and promote gut health, as well as a novel polymeric prodrug platform designed to deliver small molecules to the lower gut. ClostraBio was spun out of the University of Chicago and is incubated at Portal Innovations.

Exonate plans ‘CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease
Exonate plans ‘CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease

Business Wire

time29-07-2025

  • Business Wire

Exonate plans ‘CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease

CAMBRIDGE, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical trial for its lead candidate EXN407. The CLEAR-DE (Clinical Evaluation of a New Eye Drop for Alleviating Retinopathy in Diabetic Eye Disease) trial will further evaluate the clinical efficacy, optimal dosing and safety profile of EXN407 in patients with non-proliferative diabetic retinopathy (NPDR). The progression to a Phase IIb clinical study follows encouraging results from Exonate's Phase Ib/IIa study in March 2024. In the study, lead candidate EXN407 met its primary safety and tolerability endpoints, with no drug-related serious adverse events, and high patient compliance. Importantly, exploratory efficacy signals showed a reduction in vascular leakage, a key pathological driver in diabetic retinopathy. The Phase IIb trial to investigate the efficacy of EXN407 in NPDR patients is planned to begin in early 2026, with 140 patients currently enrolled across multiple sites in Australia, the Middle East and China. Diabetic retinopathy (DR) is a leading cause of vision loss globally. An estimated one-third of the nearly 500 million people living with diabetes are affected by NPDR, the early stage of diabetic eye disease, which can lead to more severe, vision-threatening complications. Current therapeutic approaches involve monthly intraocular injections, initiated only after symptoms appear. This limits opportunities for early therapeutic benefit, and due to the invasive nature and frequency, is often deferred until irreversible damage has occurred. EXN407 is a first-in-class, twice-daily topical formulation of a selective SRPK1 inhibitor – a minimally-invasive approach with potential to become the first effective eye-drop therapy for NPDR and diabetic macular oedema (DME). Designed to modulate expression of vascular endothelial growth factor (VEGF) via alternative mRNA splicing, EXN407 selectively inhibits the pro-angiogenic isoforms that drive disease progression, causing abnormal and leaky blood vessel formation in the retina. ' The Phase Ib/IIa data demonstrated the clear potential of EXN407 as a non-invasive treatment for diabetic eye disease, ' said Dr. Catherine Beech, Chief Executive Officer of Exonate. ' This therapy could transform the treatment landscape for early-stage disease by providing clinical benefit while avoiding the burden of injections, representing a significant advancement for patients and physicians alike. We're excited to progress to the CLEAR-DE Phase IIb trial and are actively seeking strategic partners to support its execution.' For more information about Exonate's pipeline and clinical development plans, please visit:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store